Cargando…
Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958818/ https://www.ncbi.nlm.nih.gov/pubmed/24463293 http://dx.doi.org/10.3390/ijms15021719 |
_version_ | 1782307948506120192 |
---|---|
author | Wyse, Robert D. Dunbar, Gary L. Rossignol, Julien |
author_facet | Wyse, Robert D. Dunbar, Gary L. Rossignol, Julien |
author_sort | Wyse, Robert D. |
collection | PubMed |
description | The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson’s, Alzheimer’s and Huntington’s diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs. |
format | Online Article Text |
id | pubmed-3958818 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-39588182014-03-20 Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases Wyse, Robert D. Dunbar, Gary L. Rossignol, Julien Int J Mol Sci Review The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson’s, Alzheimer’s and Huntington’s diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs. Molecular Diversity Preservation International (MDPI) 2014-01-23 /pmc/articles/PMC3958818/ /pubmed/24463293 http://dx.doi.org/10.3390/ijms15021719 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Wyse, Robert D. Dunbar, Gary L. Rossignol, Julien Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases |
title | Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases |
title_full | Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases |
title_fullStr | Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases |
title_full_unstemmed | Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases |
title_short | Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases |
title_sort | use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958818/ https://www.ncbi.nlm.nih.gov/pubmed/24463293 http://dx.doi.org/10.3390/ijms15021719 |
work_keys_str_mv | AT wyserobertd useofgeneticallymodifiedmesenchymalstemcellstotreatneurodegenerativediseases AT dunbargaryl useofgeneticallymodifiedmesenchymalstemcellstotreatneurodegenerativediseases AT rossignoljulien useofgeneticallymodifiedmesenchymalstemcellstotreatneurodegenerativediseases |